WCN25-4537 ORAL MANIFESTATIONS IN CHRONIC KIDNEY DISEASES(CKD)

Desidustat.There were no significant changes in serum potassium levels, and no major adverse cardiovascular events were reported in our follow up.All patients demonstrated good compliance with therapy.Conclusions: Desidustat is a safe and effective oral therapy for the treatment of anemia in CKD patients, offering a viable alternative to traditional erythropoietin injections considering oral route of administration.Since it does not require strict cold chain it is particularly suitable for tropical countires.Additionally, it may prove particularly efficacious in patients with ESA hypo-responsiveness.Caution needs to be exercised in excluding patients with severe uncontrolled hypertension at baseline I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.